Life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO) announced on Monday that it has signed a definitive agreement to sell its microbiology business to Astorg, a pan-European private equity firm, for approximately USD1.075bn, including cash consideration and a USD50m seller note.

The microbiology unit provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical, and food safety applications. The business generated USD645m in revenue in 2025 and operates within Thermo Fisher's Specialty Diagnostics segment.

Subject to customary closing conditions and regulatory approvals, the transaction is expected to close in the second half of 2026.

Thermo Fisher anticipates that the deal will be dilutive to adjusted earnings per share by USD0.15 in the first full year following completion.